BrainSightAI
Overview
BrainSightAI is a Bengaluru, India-based deep-tech neuroscience startup founded in 2019 by Laina Emmanuel and Rimjhim Agrawal. The company integrates artificial intelligence (AI) and neuroscience to deliver precision in neurological and psychiatric diagnostics. It has raised a total of about $5 million in pre-Series A funding, led by IAN Alpha Fund along with participation from IvyCap Ventures, Silver Needle, and other existing investors. BrainSightAI employs advanced technologies to map neural connections, significantly enhancing brain disorder diagnosis processes.
Recent Developments
- January 2025: BrainSightAI raised $5 million in a pre-series A funding round to amplify its operations across Tier 1 and Tier 2 cities in India and internationally. This funding round was led by IAN Alpha Fund with participation from IvyCap Ventures and Silver Needle. The company aims to secure FDA certification, facilitating entry into the U.S. market and exploring opportunities in Africa and Southeast Asia. Funds will also further the development of a caregiver-focused app.
- 2024: The company won the Top Innovator award at the ET Startup Awards. BrainSightAI began scaling its operations, aiming to expand from nine hospital groups to 100, planning to analyze 30-40 cases a month by year-end. The company has been expanding its offering to treat neurological and psychiatric disorders.
- 2024: BrainSightAI received recognition for its innovative approach integrating AI and neuroscience, aiding in diagnostic and treatment planning in hospitals worldwide. The company forged partnerships with over 40 hospitals in India, focusing on neurosurgery and brain tumors.
- 2023: Secured the BIRAC BIG 15 grant from the Indian government, facilitating building its healthcare technology platform. This strategic funding allowed BrainSightAI to enter clinical psychiatry, exploring new applications for its technology.
- 2022: Participated in global tech and innovation programs, receiving attention at CES and through the 3DEXPERIENCE Lab, highlighting its neuroinformatics platform, VoxelBox.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2019 |
| Headquarters | Bangalore, India |
| Founders | Laina Emmanuel, Rimjhim Agrawal |
| Revenue | Not disclosed |
| Profits | Not disclosed |
| Key Investors | IAN Alpha Fund, IvyCap Ventures, Silver Needle |
| Industry | Healthcare, AI, Medical Technology |
| Number of Employees | 30 |
Early History
BrainSightAI was founded by Laina Emmanuel, who has a background in healthcare and technology, and Rimjhim Agrawal, a Ph.D. in machine learning for psychiatry. The company originated from the Entrepreneur First program, where the founders aimed to bridge the gap between research and real-world solutions in brain diagnostics. Initially, BrainSightAI faced challenges securing interest from hospitals during the COVID-19 pandemic. However, securing grants from entities like BIRAC, as well as securing backing from early investors such as Stanford Angels and Entrepreneurs, enabled the company to survive and advance.
Company Profile and Achievements
BrainSightAI is at the forefront of integrating AI and connectomics, which is the study of neural connections in the brain, to deliver precise diagnostics for neuro-oncological and neuropsychiatric disorders. The company’s flagship products include:
- VoxelBox: An fMRI processing engine that utilizes machine learning models to provide clinicians with sophisticated insights into brain tumors and other conditions.
- Snowdrop: A patient-centric app focusing on compliance with treatment schedules and creating detailed patient profiles.
- Achievements:
- Secured various recognitions, including the Top Innovator award at the 2024 ET Startup Awards for its substantial contributions to mental health and neurology diagnostics.
- Successfully raised capital through grants and investments, which facilitated the rapid expansion of its offerings and reach.
- Expanded its platform capabilities into psychiatry, broadening its scope to address psychiatric disorders alongside neurological conditions.
Current Operations and Market Position
BrainSightAI is currently focused on enhancing its technological solutions and expanding its market presence across India and globally. The company's deep learning and AI-based platform supports neurosurgery and psychiatric treatment, providing hospitals with advanced tools to better diagnose and plan treatment for brain disorders. BrainSightAI collaborates with numerous hospitals, leveraging its platform to offer services that were previously accessible only to premier global research institutions.
Brainsightai Company Products
- Voxelbox: Enables detailed mapping and analysis of neural functions and structure using advanced neuroimaging and machine learning technologies.
- Snowdrop: Helps manage patient-care schedules and ensures adherence to treatment protocols.
- The company’s integration of AI in diagnosis aids specialists across areas like neurology and psychiatry to streamline their diagnostic processes, enhancing early detection and treatment efficiency.
Brainsightai Careers
BrainSightAI is recognized for providing cutting-edge innovations in neurodiagnostics. The company fosters a growth-oriented environment with collaborative opportunities, focusing heavily on expanding its technological edge in AI and computational neuroscience.
Brainsightai Company in Bangalore
As a Bangalore-based company, BrainSightAI positions itself strategically within India’s burgeoning technology hub, tapping into local talent and resources to fuel its expansion in healthcare technology.
Conclusion
BrainSightAI stands as a pivotal player in integrating AI with neuroscience, garnering attention for its solutions that significantly advance brain care diagnostics. With robust funding and strategic partnerships, the company is well-poised to expand its reach and impact globally. Moving forward, BrainSightAI’s innovations have the potential to transform the landscape of brain disorder diagnostics, offering promising paths for personalized and precise treatment plans worldwide.